$CYTR News

Last published 4y ago

4y agoCYTR LADXLadRx Corporation Announces OTCQB Ticker Change to LADXBusiness WireLadRx Corporation (OTCQB:LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday,
4y agoCYTRCytRx Corporation Relaunches as LadRx CorporationBusiness WireThe New LadRx Corporation Name Will Be Effective on September 26, 2022 and Will Continue to Trade Under the Ticker CYTR until the new symbol has been approved by FINRA CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical inn
4y agoCYTREuropean Patent Office Awards CytRx Key PatentBusiness WirePatent Protects the LADR Platform and Drugs Employing LADR CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has been aw
4y agoCYTRCytRx Welcomes Cary J. Claiborne to the CytRx Board of DirectorsBusiness WireMr. Claiborne Joined the CytRx Board of Directors as of the Annual Meeting CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, welcomes Mr. C
4y agoCYTRCytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common StockBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a s
4y agoCYTRCytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.Business WireKemPharm Sees Promise in Arimoclomol for Niemann-Pick Disease Type C, and Plans to Resubmit to FDA as Early as Q1 2023 CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of lif
4y agoCYTRCytRx Partners with Oncology Development Expert to Advance LADR PlatformBusiness WireCompany Begins Planning First-in-Human Studies of Next-Generation LADR Drugs CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announ
4y agoCYTRCytRx Issues Open Letter to Stockholders Regarding Recent Corporate ProgressBusiness WireThanks Stockholders for Supporting Important Proposal at Recent Special Meeting CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today iss
4y agoCYTRCytRx Announces Integration of Wholly Owned Subsidiary Centurion BioPharma and Corporate Governance UpdatesBusiness WireBelieves Integration Will Bring Enhanced Efficiency and Simplicity to the Company's Structure Notes the Company Will Fold Centurion into CytRx Dr. Louis Ignarro, Chairman of the Compensation Committee, to Retire from the Board as of the July 2022
4y agoCYTR ORPHCytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type CBusiness WireNotes CytRx's Core Assets Are Unaffected by European Medicines Agency's Assessment of Arimoclomol Highlights Positive Developments Regarding Company's Core Assets, Including Aldoxorubicin CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"),
4y agoCYTR ORPHCytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type CBusiness WireOrphazyme Intends to Request a Type C Meeting in Q2 2022 Orphazyme Plans to Resubmit the NDA During H2 2022, Subject to FDA Discussions European Medicines Agency Opinion Expected in Q1 2022 CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Compan
4y agoCYTRCytRx to Hold Town Hall for Stockholders on Thursday, January 20thBusiness WireTown Hall to be Led by New CEO Dr. Stephen Snowdy CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today
4y agoCYTRCytRx to Participate in the H.C. Wainwright BioConnect Virtual ConferenceBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that John Caloz, the Company's Chief Financ
4y agoCYTRCytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive OfficerBusiness WireDr. Snowdy to Succeed Steven A. Kriegsman, Who is Stepping Down as CEO and Chairman of the Board CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development in oncology and
4y agoCYTR IBRXCytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of CancerBusiness WireNotes Aldoxorubicin is Currently Being Studied in Treatment of Pancreatic Cancer, Triple Negative Breast Cancer and Head and Neck Cancer CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on res
4y agoCYTRCytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, NevadaBusiness WireIssues Presentation on Plans, Including Potential Sources of Funding and Benefits to the Las Vegas Community Highlights Centurion BioPharma's Recent Momentum in the Research and Development of Cancer Drugs CytRx Corporation (OTCQB:CYTR) ("CytRx" o
5y agoCYTR IBRX ORPHCytRx Comments on Quarterly Results and Recent Strategic InitiativesBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the quarter ended Septem
5y agoCYTR ORPHCytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type CBusiness WireFDA Recommends Orphazyme Provides Supplemental Information and Analyses FDA Offers to have Further Interactions with Orphazyme to Identify Path to Resubmission for Arimoclomol in NPC CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a spe
5y agoCYTR IBRXCytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer TreatmentBusiness WireHighlights Early Efficacy of CytRx's Licensed Drug Aldoxorubicin in ImmunityBio's Phase 2 Trial of Nant Cancer Vaccine for Third Line or Greater Pancreatic Cancer Patients Notes 90% of All Evaluable Patients and 87% of Patients With Extremely Advance
5y agoCYTRCytRx to Present at Upcoming Virtual LD Micro ConferenceBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chie
5y agoCYTRCytRx to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, the Company's Cha
5y agoCYTR IBRX ORPH PBLACytRx Comments on Quarterly Results and Recent Strategic InitiativesBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the second quarter ended
5y agoCYTR DCTH IBRX LLY+2CytRx Announces Director Election Results from 2021 Annual Meeting of StockholdersBusiness WireNew Director Dr. Jennifer K. Simpson Added to CytRx Board of Directors CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative dise
5y agoCYTR IBRX ORPHCytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022Business WireImmunityBio's Receipt of U.S. Patent for Novel Immunotherapy, NANT Cancer Vaccine, Being Studied in Multiple Clinical Trials CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and de
5y agoCYTR IBRX ORPHCytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional InvestorBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced the closing of its previously announced sal
5y agoCYTR IBRX ORPHCytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional InvestorBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that it has entered into a securities purch
5y agoCYTR ORPHCytRx Comments on Orphazyme's Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type CBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on Orphazyme A/S's (NASDAQ:ORPH) ("Orphazyme") recently anno
5y agoCYTR ORPHCytRx Notes Orphazyme's Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type CBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") announced it has
5y agoCYTRCytRx to Present at Upcoming Investor ConferencesBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today announced that Steven A. Kriegsman, Chairman and Chie
5y agoCYTR IBRX ORPHCytRx Comments on Quarterly Results and Year-to-Date ProgressBusiness WireContinues Focusing on Near-Term Revenue Opportunities Linked to Orphazyme's Potential Regulatory Approvals for Arimoclomol in the Treatment of Niemann-Pick Disease Type C CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopha
5y agoCYTR ORPHCytRx Notes Topline Data From Trial of Arimoclomol in Amyotrophic Lateral SclerosisBusiness WireCytRx Corporation (OTCQB:CYTR) ("CytRx"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today noted that Orphazyme A/S (NASDAQ:ORPH) ("Orphazyme") announced that th
8y agoCYTRCytRx Corporation (CYTR) Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
8y agoCYTRCytRx's (CYTR) CEO Steve Kriegsman on Q4 2017 Results - Earnings Call TranscriptEarnings Call Transcripts